Rerouting cardiovascular management following gastric bypass surgery: Dose optimization of carvedilol using...

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Metabolism

Background:

• Roux-en-Y gastric bypass (RYGB) alters drug pharmacokinetics (PK).
• Carvedilol, a beta-blocker, undergoes metabolism influenced by various enzymes and transporters.
• Understanding carvedilol PK/PD in RYGB patients is essential for effective treatment.

Purpose of the Study:

• To investigate the impact of RYGB on carvedilol PK using population-based PK modeling.
• To develop a PK/PD link model to optimize carvedilol dosing in post-RYGB patients.
• To evaluate the effect of RYGB on carvedilol enantiomer absorption and bioavailability.

Main Methods:

• Population PK modeling (PopPK) utilized data from 52 subjects (nonobese, obese, post-RYGB).
• Covariate analysis included RYGB history, CYP2D6/CYP3A4 activity, and intestinal transporter expression.
• An inhibitory Emax PK/PD model linked (S)-carvedilol PK to exercise-induced heart rate changes.

Main Results:

• RYGB reduced carvedilol oral bioavailability by 50% and delayed absorption.
• Increased ABCC2 mRNA expression correlated with delayed Tmax.
• Reduced (S)-carvedilol exposure (AUC) post-RYGB led to a 33% decrease in the 24-hour beta-blocker effect (AUEC).

Conclusions:

• Standard carvedilol dosing is inadequate for RYGB patients, resulting in diminished beta-blockade.
• A 50-mg daily dose in post-RYGB patients may achieve similar exposure and effect as 25 mg in nonoperated individuals.
• Personalized dosing strategies are vital for achieving therapeutic goals in RYGB patients taking carvedilol.